Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Lucie Ellis
Oxford, UK-based Immunocore, which is developing immunotherapies against cancer, has secured $40m in funding from the Bill & Melinda Gates Foundation to boost its research activities in infectious diseases. The company hopes to develop novel therapeutics to reduce treatment timelines and improve outcomes for patients with HIV and TB.
Ahead of a regulatory verdict in the US, GSK's triple combination therapy for COPD, Trelegy Ellipta, has won a positive recommendation in Europe.
Emerging Company Profile: Prima BioMed, a biotech developing immuno-oncology medicines, has been patiently waiting in the wings. Now, with three of its LAG-3 drug candidates partnered with pharma players, the company is ready to take center stage.
Shionogi is on track to file its novel flu treatment S-033188 with regulators in Japan by the end of the year on the back of positive Phase III data.
GSK's closed triple combination for COPD, Trelegy, is expected to get a green light for approval in Europe on Friday – but the product will be fighting for market share against Chiesi's triple combination Trimbow, which has a head start.
Despite returning positive results in the MONARCH-3 trial, Lilly's breast cancer therapy abemaciclib has sparked mixed reactions at ESMO; the big pharma will need to work on differentiating the drug from other CDK 4/6 therapies.